Chinese Biotech Drug Licensing Deals Surge: $12B in Global Out-Licensing Revenue
Chinese biotech companies signed over $12 billion in out-licensing deals with Western pharmaceutical companies in 2025, signalling a shift from low-cost API manufacturing to innovation-driven pharmaceutical exports.
- Out-licensing deal volumes and values
- From API supplier to innovation exporter
- ADC technology as a case study
- Regulatory pathways and market access
- Implications for global pharmaceutical supply chains
Out-licensing deal volumes and values#
Chinese biotech companies signed 87 out-licensing deals with global pharmaceutical partners in 2025, totalling over $12 billion in upfront payments and potential milestone values. This represents a threefold increase from 2022 levels and positions China as the second-largest source of licensed drug candidates after the United States. Companies including BeiGene, Legend Biotech, Hengrui Medicine, and Innovent Biologics have all completed billion-dollar deals with partners including Johnson & Johnson, Novartis, and AbbVie. The deals span oncology, immunology, and metabolic disease, with ADC technology being a particular area of Chinese competitive strength.
From API supplier to innovation exporter#
China's pharmaceutical export profile has historically been dominated by active pharmaceutical ingredients and generic drug manufacturing, with the country supplying roughly 40% of global API volumes. The surge in out-licensing represents a qualitative shift toward exporting intellectual property rather than commoditised manufacturing services. Chinese biotech companies benefit from lower clinical trial costs, large patient populations for rapid enrollment, and increasing regulatory harmonisation with ICH standards. This transition mirrors the broader pattern of Chinese industrial upgrading observed in electronics, automotive, and other sectors where initial cost advantages evolve into technology leadership.
ADC technology as a case study#
Chinese companies have developed particular expertise in antibody-drug conjugate technology, with over 40 ADC candidates in clinical development outside China as of 2025. Legend Biotech's partnership with Johnson & Johnson on the CAR-T therapy Carvykti generated blockbuster revenues and validated the Chinese biotech licensing model. Multiple Chinese ADC developers have signed deals exceeding $1 billion in total potential value, attracting global pharma companies seeking to replenish their oncology pipelines. The concentration of ADC expertise reflects China's strategy of targeting specific therapeutic modalities where rapid iteration and manufacturing scale can create competitive advantages.
Data-backed guides on AI, eCommerce, and SME strategy — straight to your inbox.
Regulatory pathways and market access#
Chinese drug candidates licensed to Western partners typically undergo further clinical development and regulatory review in the US and EU markets under the partner's sponsorship. The NMPA's increasing alignment with ICH guidelines has improved the transferability of Chinese clinical data to Western regulatory submissions, reducing the need for duplicate trials. However, political scrutiny of Chinese-origin pharmaceuticals has intensified, with some US legislators proposing restrictions on federal healthcare programme coverage of drugs developed in China. Biotech licensing deals are structured to navigate these concerns by transferring manufacturing and development responsibilities to the Western partner for regulated markets.
Implications for global pharmaceutical supply chains#
The growth of Chinese pharmaceutical innovation creates both opportunities and dependencies for global healthcare systems. Western pharmaceutical companies gain access to diverse drug candidates at lower development costs, potentially accelerating the pace of new treatment availability. However, the concentration of certain therapeutic expertise in Chinese biotech raises questions about supply chain resilience and geopolitical risk in healthcare. Companies involved in pharmaceutical trade should monitor the evolving regulatory landscape for Chinese-origin drug products and assess both the commercial opportunities and compliance requirements of engaging with Chinese biotech partners.
People also ask
How much are Chinese biotech licensing deals worth?
Chinese biotech companies signed over $12 billion in out-licensing deals with global pharmaceutical partners in 2025, with individual deals reaching over $1 billion in total potential value including milestones.
What drugs is China exporting?
China is increasingly exporting innovative drug candidates through licensing deals rather than finished products, particularly in antibody-drug conjugates, CAR-T therapies, and novel oncology treatments developed by companies like BeiGene, Legend Biotech, and Hengrui Medicine.
Is Chinese biotech competitive with Western pharma?
In specific therapeutic areas like ADCs and CAR-T, Chinese biotech companies have reached global competitiveness, with over 40 Chinese-origin ADC candidates in clinical development outside China and multiple billion-dollar licensing deals with major Western pharmaceutical companies.
Our team combines expertise in data analytics, SME strategy, and AI tools to produce practical guides that help founders and operators make better business decisions.
Turn trade intelligence into action
Upload your import/export data and let AskBiz analyse your China trade exposure, margins, and opportunities.
Start free — no credit card required →